Literature DB >> 28766047

Prognostic value of cardiovascular magnetic resonance imaging for life-threatening arrhythmia detected by implantable cardioverter-defibrillator in Japanese patients with hypertrophic cardiomyopathy.

Yasuki Hen1, Mayuko Tsugu-Yagawa2, Nobuo Iguchi2, Yuko Utanohara2, Kaori Takada3, Haruhiko Machida4, Ayako Takara2, Kunihiko Teraoka2, Kanki Inoue2, Itaru Takamisawa2, Morimasa Takayama2, Tsutomu Yoshikawa2.   

Abstract

Implantable cardioverter-defibrillator (ICD) is effective to prevent sudden death in HCM patients. We reviewed ICD records to analyze the relation between life-threatening arrhythmia and late gadolinium enhancement (LGE) on cardiovascular magnetic resonance (CMR) in Japanese hypertrophic cardiomyopathy (HCM) patients. In 102 consecutive patients (median age 63 years, 63 males) implanted with an ICD after CMR with gadolinium enhancement (median follow-up 2.8 years), the outcome of life-threatening arrhythmic events (appropriate ICD interventions for ventricular tachycardia or ventricular fibrillation) was examined. Appropriate interventions rate were 10.3% per year for secondary prevention and 7.4% per year for primary prevention. The annualized ICD-related complication rate was 3.7%. 43/91 patients (47%) implanted ICD for primary prevention had maximum wall thickness ≥20 mm plus LGE in ≥4 of 17 left ventricular segments (cut-off value obtained from ROC curve); the appropriate ICD intervention rate was significantly higher in this group than in other patients group (annualized event rate, 11.1 vs. 4.6%; log-rank P = 0.038). A combination of myocardial hypertrophy and LGE is a useful outcome predictive factor for life-threatening ventricular arrhythmia in Japanese HCM patients.

Entities:  

Keywords:  Cardiac magnetic resonance; Hypertrophic cardiomyopathy; Implantable cardioverter-defibrillator; Late gadolinium enhancement; Ventricular arrhythmia

Mesh:

Year:  2017        PMID: 28766047     DOI: 10.1007/s00380-017-1030-3

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  26 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  Circulation       Date:  2011-11-08       Impact factor: 29.690

3.  Risk Markers and Appropriate Implantable Defibrillator Therapy in Hypertrophic Cardiomyopathy.

Authors:  Peter Magnusson; Fredrik Gadler; Per Liv; Stellan Mörner
Journal:  Pacing Clin Electrophysiol       Date:  2016-01-21       Impact factor: 1.976

4.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).

Authors:  Constantinos O'Mahony; Fatima Jichi; Menelaos Pavlou; Lorenzo Monserrat; Aristides Anastasakis; Claudio Rapezzi; Elena Biagini; Juan Ramon Gimeno; Giuseppe Limongelli; William J McKenna; Rumana Z Omar; Perry M Elliott
Journal:  Eur Heart J       Date:  2013-10-14       Impact factor: 29.983

5.  Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy: patient outcomes, rate of appropriate and inappropriate interventions, and complications.

Authors:  Pieter A Vriesendorp; Arend F L Schinkel; Johan Van Cleemput; Rik Willems; Luc J L M Jordaens; Dominic A M J Theuns; Marjon A van Slegtenhorst; Thomy J de Ravel; Folkert J ten Cate; Michelle Michels
Journal:  Am Heart J       Date:  2013-07-16       Impact factor: 4.749

6.  Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.

Authors:  Hong-Mi Choi; Kyung-Hee Kim; Joo Myung Lee; Yeonyee E Yoon; Seung-Pyo Lee; Eun-Ah Park; Whal Lee; Yong-Jin Kim; Goo-Yeong Cho; Dae-Won Sohn; Hyung-Kwan Kim
Journal:  Heart       Date:  2015-04-20       Impact factor: 5.994

7.  Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy.

Authors:  Raymond H Chan; Barry J Maron; Iacopo Olivotto; Michael J Pencina; Gabriele Egidy Assenza; Tammy Haas; John R Lesser; Christiane Gruner; Andrew M Crean; Harry Rakowski; James E Udelson; Ethan Rowin; Massimo Lombardi; Franco Cecchi; Benedetta Tomberli; Paolo Spirito; Francesco Formisano; Elena Biagini; Claudio Rapezzi; Carlo Nicola De Cecco; Camillo Autore; E Francis Cook; Susie N Hong; C Michael Gibson; Warren J Manning; Evan Appelbaum; Martin S Maron
Journal:  Circulation       Date:  2014-08-05       Impact factor: 29.690

8.  Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.

Authors:  Christian Prinz; Maria Schwarz; Ivan Ilic; Kai Thorsten Laser; Roman Lehmann; Eva-Maria Prinz; Thomas Bitter; Jürgen Vogt; Frank van Buuren; Nikola Bogunovic; Dieter Horstkotte; Lothar Faber
Journal:  Can J Cardiol       Date:  2012-06-30       Impact factor: 5.223

9.  Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Authors:  David A Begley; Saidi A Mohiddin; Dorothy Tripodi; Judith B Winkler; Lameh Fananapazir
Journal:  Pacing Clin Electrophysiol       Date:  2003-09       Impact factor: 1.976

10.  Syncope and risk of sudden death in hypertrophic cardiomyopathy.

Authors:  Paolo Spirito; Camillo Autore; Claudio Rapezzi; Paola Bernabò; Roberto Badagliacca; Martin S Maron; Sergio Bongioanni; Fabio Coccolo; N A Mark Estes; Caterina S Barillà; Elena Biagini; Giovanni Quarta; Maria Rosa Conte; Paolo Bruzzi; Barry J Maron
Journal:  Circulation       Date:  2009-03-23       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.